8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Incyte reports Q2 revenue growth and raises 2026 sales guidance
Filed with the SEC on · Summarized by InvestorsBot
Incyte reported second-quarter 2026 revenue of $1.67 billion, up 38% year over year, and net income of $585.6 million, or $2.81 diluted EPS; net sales rose 40% to $1.49 billion, including a one-time, non-cash $246 million Opzelura benefit tied to its CMS agreement. The company raised 2026 total net sales guidance to $5.13 billion-$5.26 billion and expects higher operating expenses, including an approximately $1.27 billion third-quarter charge related to its $1.25 billion acquisition of Vega Therapeutics, whose seller may receive up to $750 million in additional sales-milestone payments.